On March 1, 2019, the Countermeasures Symposium on AI Development in Medical Field sponsored by China National Center for Biotechnology Development was held in Beijing. Over 30 expert representatives from Center for Medical Device Evaluation under NMPA, National Institutes for Food and Drug Control, universities, scientific research institutions, enterprises, hospitals, etc., and part of experts of “Research and Development of Digital Medical Devices” team were present at the symposium. The symposium was presided over by the director of Chemical Medicine and Medical Device Section, China National Center for Biotechnology Development.
By introducing the background and objectives of this symposium first, the host encouraged all attending representatives to conduct deep discussions covering all aspects of AI development in medical field, including the status quo of technology, application prospect, general problems and supervision demand. Then, some enterprise representatives and clinical experts exchanged ideas pertinent to the R&D, clinical application, development prospect and existing problems of such AI products for medical imaging, electrophysiology, pathological diagnosis, motion analysis, etc. Conversations related to inspection and registration, supervision demand, technology allocation, etc. of AI products for medical purposes were also conducted among representatives from National Institutes for Food and Drug Control, Center for Medical Device Evaluation under NMPA and China National Center for Biotechnology Development, and suggestions for the technology obstacle of AI products for medical purposes were also put forward. The symposium may provide some feasible clues to perfect the policies for medical AI and help blaze a development path appropriate to China and the clinical features of medical AI.
By introducing the background and objectives of this symposium first, the host encouraged all attending representatives to conduct deep discussions covering all aspects of AI development in medical field, including the status quo of technology, application prospect, general problems and supervision demand. Then, some enterprise representatives and clinical experts exchanged ideas pertinent to the R&D, clinical application, development prospect and existing problems of such AI products for medical imaging, electrophysiology, pathological diagnosis, motion analysis, etc. Conversations related to inspection and registration, supervision demand, technology allocation, etc. of AI products for medical purposes were also conducted among representatives from National Institutes for Food and Drug Control, Center for Medical Device Evaluation under NMPA and China National Center for Biotechnology Development, and suggestions for the technology obstacle of AI products for medical purposes were also put forward. The symposium may provide some feasible clues to perfect the policies for medical AI and help blaze a development path appropriate to China and the clinical features of medical AI.